These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36943397)

  • 21. Erdafitinib for locally advanced or metastatic urothelial carcinoma.
    Siefker-Radtke AO; Loriot Y
    Am J Health Syst Pharm; 2022 May; 79(11):824-825. PubMed ID: 35147178
    [No Abstract]   [Full Text] [Related]  

  • 22. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
    Weaver A; Bossaer JB
    J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.
    Noeraparast M; Krajina K; Pichler R; Niedersüß-Beke D; Shariat SF; Grünwald V; Ahyai S; Pichler M
    Cancer Commun (Lond); 2024 Oct; 44(10):1189-1208. PubMed ID: 39161208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma.
    Castro-Alonso FJ; Beas-Lozano E; Remolina-Bonilla YA; Flaig TW; Bourlon MT
    Oncology (Williston Park); 2023 Jun; 37(6):256-261. PubMed ID: 37343207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypoxia regulates the expression and localization of CCAAT/enhancer binding protein α by hypoxia inducible factor-1α in bladder transitional carcinoma cells.
    Xue M; Li X; Chen W
    Mol Med Rep; 2015 Aug; 12(2):2121-7. PubMed ID: 25824695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
    Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
    Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells.
    Ohtsu A; Arai S; Sawada T; Kato M; Maeno Y; Miyazawa Y; Fujizuka Y; Sekine Y; Koike H; Matsui H; Suzuki K
    Biochem Biophys Res Commun; 2022 Nov; 628():76-83. PubMed ID: 36084554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ipatasertib (GDC-0068) and erdafitinib co-treatment for inducing mitochondrial apoptosis through Bim upregulation in bladder cancer cells.
    Hu C; Shang X; Zheng T; Hu X; Zhao Y
    Biochem Biophys Res Commun; 2022 May; 604():165-171. PubMed ID: 35306249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data.
    Ronan K; Jordan E; Leonard C; McDermott R
    Ir J Med Sci; 2024 Jun; 193(3):1155-1161. PubMed ID: 37947995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
    Groeneveld CS; Sanchez-Quiles V; Dufour F; Shi M; Dingli F; Nicolle R; Chapeaublanc E; Poullet P; Jeffery D; Krucker C; Maillé P; Vacherot F; Vordos D; Benhamou S; Lebret T; Micheau O; Zinovyev A; Loew D; Allory Y; de Reyniès A; Bernard-Pierrot I; Radvanyi F
    Eur Urol; 2024 May; 85(5):483-494. PubMed ID: 37380559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erdafitinib: First Global Approval.
    Markham A
    Drugs; 2019 Jun; 79(9):1017-1021. PubMed ID: 31161538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erdafitinib to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2019 Aug; 55(8):495-501. PubMed ID: 31461086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
    Rose TL; Weir WH; Mayhew GM; Shibata Y; Eulitt P; Uronis JM; Zhou M; Nielsen M; Smith AB; Woods M; Hayward MC; Salazar AH; Milowsky MI; Wobker SE; McGinty K; Millburn MV; Eisner JR; Kim WY
    Br J Cancer; 2021 Oct; 125(9):1251-1260. PubMed ID: 34294892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
    Ascione CM; Napolitano F; Esposito D; Servetto A; Belli S; Santaniello A; Scagliarini S; Crocetto F; Bianco R; Formisano L
    Cancer Treat Rev; 2023 Apr; 115():102530. PubMed ID: 36898352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma.
    Kardoust Parizi M; Margulis V; Lotan Y; Mori K; Shariat SF
    Urol Oncol; 2021 Jul; 39(7):409-421. PubMed ID: 33642228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells.
    Li Y; Zhao X; Tang H; Zhong Z; Zhang L; Xu R; Li S; Wang Y
    Urol Int; 2012; 88(1):95-101. PubMed ID: 22041818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation.
    Ouyang Y; Ou Z; Zhong W; Yang J; Fu S; Ouyang N; Chen J; Xu L; Wu D; Qian J; Lin Y; Lin T; Huang J
    Cancer Res; 2023 Dec; 83(24):4030-4046. PubMed ID: 37768887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FGFR alterations in urothelial carcinoma: Picking the right target.
    Hubert P; Selmani Z; Loriot Y; Thiery-Vuillemin A
    Bull Cancer; 2021 Jun; 108(6):566-570. PubMed ID: 34020787
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.